Skip to main content
ChemPartner PharmaTech Co., Ltd. logo

ChemPartner PharmaTech Co., Ltd. — Investor Relations & Filings

Ticker · 300149 ISIN · CNE100000Y27 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,256 across all filing types
Latest filing 2018-04-02 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300149

About ChemPartner PharmaTech Co., Ltd.

https://www.chempartner.com

ChemPartner PharmaTech Co., Ltd. is a global research and development organization providing comprehensive drug discovery and development services. Operating as a Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), the company supports pharmaceutical and biotechnology clients through an integrated service platform. Core capabilities include medicinal chemistry, biology, pharmacology, drug metabolism and pharmacokinetics (DMPK), and toxicology. The organization also offers specialized expertise in biologics discovery, protein engineering, and antibody development. ChemPartner facilitates the transition from early-stage research to clinical development through its pharmaceutical development and manufacturing capabilities, utilizing advanced technology to accelerate the discovery and production of novel therapeutic agents.

Recent filings

Filing Released Lang Actions
关于公司发行股份及支付现金购买资产暨关联交易项目变更签字注册会计师的说明
Audit Report / Information Classification · 95% confidence The document is a formal letter from the auditing firm PwC Zhongtian regarding a change in the signing auditors for a major asset restructuring project of Quantum Hi-Tech (China) Biological Co., Ltd. It confirms the authenticity and accuracy of previously issued audit reports and states the change in the signing auditors. The document is addressed to the China Securities Regulatory Commission and is related to audit services for a specific transaction. It does not contain full financial statements or detailed audit results but serves as an official explanation and certification regarding auditor changes. Therefore, it fits the category of Audit Report / Information (AR), as it pertains to audit-related information and auditor signatory changes for a specific audit engagement, rather than a full annual report or a simple announcement of report publication.
2018-04-02 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a change in accounting policies by the company Quantum Hi-Tech (China) Biological Co., Ltd. It details the reasons for the change, the specific accounting standards involved, the approval process by the board and supervisory committee, and the opinions of independent directors and the supervisory board. The document does not contain actual financial statements or detailed financial data but rather explains the policy change and its impact. It is a regulatory announcement about accounting policy changes, not a full financial report or audit report. Given the content and length (2415 characters), it fits best as a Regulatory Filing (RNS) rather than an Audit Report or Annual Report. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2018-04-02 Chinese
2017年年度报告
Annual Report Classification · 100% confidence The document is titled as the "2017 年年度报告全文" which translates to "2017 Annual Report Full Text" for Quantum Hi-Tech (China) Biological Co., Ltd. It contains detailed sections typical of an annual report, including company overview, financial data, risk factors, business summary, and governance information. The length is substantial (15,000 characters), and it includes comprehensive financial and operational data for the fiscal year 2017. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K).
2018-04-02 Chinese
独立董事关于评估机构的独立性、评估假设前提的合理性、评估方法与评估目的相关性及评估定价的公允性的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent opinion from the independent directors regarding the independence of the valuation agency, the reasonableness of valuation assumptions, the relevance of valuation methods to the purpose, and the fairness of the valuation pricing related to a major asset restructuring transaction. It references specific valuation reports and legal compliance but does not contain financial statements or detailed financial data itself. The document is a formal opinion related to a major asset acquisition transaction, not a full report or announcement of voting results. It fits best under Regulatory Filings (RNS) as it is a compliance-related disclosure that does not fit other specific categories like M&A filings or audit reports.
2018-04-02 Chinese
关于举办2017年度网上业绩说明会的通知
Investor Presentation Classification · 90% confidence The document is a notice about holding an online performance briefing for the fiscal year 2017, scheduled on April 10, 2018. It mentions the participation of company executives and invites investors to join the webcast. The document is short (492 characters) and serves as an announcement for an upcoming event rather than the event transcript or detailed financial report itself. This fits the description of an Investor Presentation (IP) announcement or a Call Transcript (CT) if it were the transcript. However, since this is a notice about the event, it is best classified as an Investor Presentation (IP) type, as it relates to a performance briefing for investors. Confidence is high due to clear mention of an annual performance briefing and the presence of senior management.
2018-04-02 Chinese
独立董事2017年度述职报告（王林）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2017 Annual Work Report" for the company Quantum Hi-Tech (China) Biological Co., Ltd. It details the independent director's attendance at meetings, opinions on company matters, committee work, investigations, investor protection efforts, training, and other duties during the 2017 fiscal year. The content is a narrative report of the independent director's activities and opinions rather than a financial report or regulatory filing. It is not an announcement of voting results, a proxy statement, or a remuneration report. It is also not a certification or a short announcement but a substantive report on the director's work. Therefore, it fits best under Board/Management Information (MANG), which covers announcements related to board or senior management activities, including independent director reports.
2018-04-02 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.